

DATA MANAGEMENT PRINCIPLES

DEVERICK J. ANDERSON, MD, MPH, FSHEA, FIDSA

DIRECTOR, DUKE CENTER FOR ANTIMICROBIAL STEWARDSHIP AND INFECTION PREVENTION

SHEA ANTIMICROBIAL STEWARDSHIP RESEARCH WORKSHOP – NOVEMBER 2016

Disclosures

Research grants – AHRQ, NIH/NIAID, CDC

Royalties – UpToDate



Disclosures



Outline

Background

Quality control/Quality assurance (QC/QA)

- The details are important
- Throughout study execution
 - Planning
 - During
 - Post

Two points of emphasis for today

- Internal validity
- Data validation

Take home points

Background

Data is fundamental in epidemiological and stewardship research

- Cause and effect

Researchers faced with the inevitable question:

- DO I BELIEVE WHAT I SEE??

ANSWER: Depends on quality of data


Data journey mirrors the study journey

Caveat: no such thing as a perfect (error- or bias-free) study

- Goal: minimize error and bias to greatest extent possible

QUALITY ASSURANCE

QUALITY CONTROL



DATA

Quality Control & Quality Assurance

Manufacturing

- QC – inspect products at the end of the manufacturing line and remove substandard products
- QA – improve all procedures to improve overall quality of the products
 - Focus on process not product

Research

- QA – practices to minimize systematic bias implemented **before** data collection
- QC – practices to minimize bias **during** and **after** data collection (correct mistakes identified)

Data management is a part of QC/QA procedures

- Most literature related to clinical trials

QUALITY ASSURANCE

QUALITY CONTROL

Protocol development
Documentation
Personnel: training/certification
Ethics (IRB)

PLANNING

DURING (CONDUCT)

POST

Data collection tools
Data validation planning
Data management planning
Pilot data collection?

DATA



Study Protocol

Outlines all the steps of the study process **before** the study begins

- QA/QC procedures
- Data management
- Statistical analysis plan

Time-consuming and burdensome

But worth it

- Use as the “map” for your journey



Study Protocol

Study objectives

Outcomes

- Primary
- Secondary

Study design

Populations (participants)

- Inclusion
- Exclusion

Variables

Data collection tool

Data collection strategy

Data validation steps

Statistical analysis plan

- Sample size and power

Internal Validity (vs. External Validity)

Internal validity – how well was the study performed?


- Study execution
- Steps to limit bias/confounding
 - Systematic bias

External validity – do results apply to other settings?

- Generalizability
- Repeat process (and get same results)

QUALITY ASSURANCE

QUALITY CONTROL



DATA



Data Management Plan

How do you turn “raw” data to analyzable, “valid” data?

Errors can (and do occur) at every step

- Primary data
- Data extraction
 - Electronic data transfer
 - Transcription/entry into a database
- Processing (coding), storage
- Analysis

Data Management Plan - Tips

Identify data sources

- Familiarize yourself with type(s) of data available
- Manual collection
- Backup ALL raw data

Create data dictionary

- Train data abstractors

Develop data collection tools

Develop electronic database

- Data entry – predefined choices
 - MINIMIZE FREE TEXT
- Relational – need identifiers to connect databases
 - Unique to subject but present in all databases

Pilot tools and methods

- Modify

Collect data


Clean and validate data

Outline security steps

Data Dictionary

| | A | B | C | D |
|----|---------------------------|--------------|------------------------|-------------------|
| 1 | Category | Field | Definition | Source |
| 2 | | | | |
| 3 | Background Data | MRN | Database MRN | Demographic table |
| 4 | | Age | Update Query | |
| 5 | | Sex | 1 Female | |
| 6 | | | 2 Male | |
| 7 | | Race | 1 White | |
| 8 | | | 2 Black | |
| 9 | | | 3 Asian | |
| 10 | | | 4 Hispanic | |
| 11 | | | 5 Other | |
| 12 | | | 6 DK (unknown) | |
| 13 | | | 7 American Indian | |
| 14 | ADLs at Admission | Ambulate | 0, 1 | Nurse admission |
| 15 | 0 Independent | Bathing | 0, 1 | |
| 16 | 1 Needs Assistance | Dressing | 0, 1 | |
| 17 | | Bcontin | 0 Continent | |
| 18 | | | 1 Incontinent | |
| 19 | | | 2 colostomy | |
| 20 | | Ucontin | 0 Continent | |
| 21 | | | 1 Incontinent, 2 Foley | |
| 22 | | Feeding | 0, 1, 2=tube feeding | |
| 23 | Discharge | DischDis | Discharge Disposition | Discharge summary |
| 24 | | | 1 Home | |
| 25 | | | 2 Home Health | |
| 26 | | | 3 Rehab | |
| 27 | | | 4 Nursing Home | |
| 28 | | | 5 Dead | |
| 29 | | | 6 Other | |
| 30 | | | 7 Other Hospital | |
| 31 | | | 8 AMA | |
| 32 | | | 9 Hospice | |





Data Validation

Multistep process to ensure data collected represent “truth”

- Improve “accuracy”

Approach depends on type of data

Requires some type of “gold standard”

Commonly used strategies for manual abstraction:

- Multiple reviewers
- Random sample
- Key variables
- Check completeness of data collection



Data Validation - Datasets

Large datasets still need to undergo validation

Can use some of the same strategies

- Completeness of data

Additional strategies

- All variables present
- Error checking (“out of range”)
 - Dates
- New variables (drug names?)

Think about perspective

- Review of data already in dataset confirms that what you have may be accurate
- But, doesn’t confirm that ALL data are present

KEY POINT: these datasets weren’t created for your research project!

Data Validation - Datasets

DATASET


RANDOM PATIENT SAMPLE


Table 3. Antimicrobial Agents and Routes Captured in Sample eMAR File.

| Drug | On Report | On Report NF- | Not Used | Missing | Route Validation | Drug | On Report | On Report NF- | Not Used | Missing | Route Validation |
|-----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-----------------------|-------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-----------------------|
| Acyclovir | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | IV Y/N PO/VT Y/N | Fidaxomicin | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Amantadine | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | Fluconazole | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Amikacin | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | IV Y/N Inhaled Y/N | Foscarnet | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Amoxicillin | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | Fosfomycin | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Amoxicillin/ Clavulanate | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | Ganciclovir | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Amphotericin B | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | Gemifloxacin | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Amphotericin B liposomal | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | Gentamicin | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | IV Y/N Inhaled Y/N |
| Ampicillin | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | Imipenem/ Cilastatin | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |

Table 4. Manual Validation of Patient Records as compared to sample eMAR file.

| | Patient MRN | Date(s) | Unit | Comments |
|----|-------------|---------|------|----------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |
| 11 | | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | | | | |





Beware the Preexisting Database

Key consideration in study design – prospective vs. retrospective

- Retrospective study designs more prone to various types of bias

Some advantages

- Decrease time/effort
- Availability
- Limited/de-identified

Just because data exist, doesn't mean should be used for your study

- Incomplete
- Not validated

Preexisting Data – Surveillance Data

Statewide review of CLABSI surveillance data in Connecticut

Trained reviewers from DPH acted as “gold standard”

- Reviewed positive blood cultures from 30 hospitals

Results: >50% underreporting of CLABSI

| CT DPH reviewers | CT hospital reports to the National Healthcare Safety Network | | |
|------------------|---|-----------|-------|
| | CLABSI | No-CLASBI | Total |
| CLABSI | 23 | 25 | 48 |
| No-CLABSI | 4 | 424 | 428 |
| Total | 27 | 449 | 476 |

Preexisting Data – Surveillance Data

Similar study in Oregon

Largely same results, but variation across hospitals

| Change in CLABSI incidence after validation | No. (%) ^a of hospitals |
|---|-----------------------------------|
| Decreased by 0.70 | 1 (2) |
| No change | 33 (75) ^b |
| Increased by 0.01–0.50 | 2 (5) |
| Increased by 0.51–1.00 | 2 (5) |
| Increased by more than 1.00 | 6 (14) ^c |
| Total | 44 (100) |

Preexisting Data – Billing Data

Review of CLABSI data from 3 hospitals

- Surveillance (IC) vs. billing (ICD-9, used for HAC)

| Variable | No. (%) of cases | Sensitivity, % | PPV |
|-----------------------|------------------|----------------|-----|
| Overall ($n = 890$) | | 14 | 55 |
| Concordant | 112 (13) | ... | ... |
| IC only | 686 (77) | ... | ... |
| HAC only | 92 (10) | ... | ... |

Preexisting Data – Administrative Data

Pharmacy administrative databases different from administration databases (eMAR)

- Cost/purchasing

32 units in Canada


- Compared DDD from pharmacy system to DDD from eMAR

Pharmacy DDD – eMAR DDD

Average differences:

24% for PO abx

57% for IV abx



Duke Center for
Antimicrobial Stewardship
and Infection Prevention

Beware the Preexisting Database

Don't fit your question to the data, find data that fit your question

Bottom Line: Don't avoid retrospective research with preexisting dataset, **KNOW LIMITATIONS**

- Data inaccuracies (“noise”) stable over time?
- Know strategies to improve quality

HYPOTHETICAL EXAMPLE



Stewardship Hypothetical Example

Objective: to determine if restriction vs. post-Rx review leads to better utilization of antimicrobial therapy

Protocol development

- Define interventions
- Eligible patients
- Location
- Statistician

Example – Data Management

Data source: _____

- Obtain utilization data from eMAR
- OTHER?
- Save raw file

Data dictionary – Key variable:

Electronic database: _____

- Need identifiers to link datasets

Data validation strategy: _____

Data collection: _____



Special Scenario – Multicenter Research

Multicenter research ultimately preferred

- Increases external validity

Complexity of data management increased

- Number of centers = number of different ways a process might happen

Data management plan developed centrally and distributed to participating centers

- QA/QC
 - Participating centers must perform local QA/QC
 - Central location likely adds an additional layer of QA/QC
 - Data checks
 - Data feedback/reports for participating centers

Central location must have a system to receive data from all participating centers



Take Home Points

Data management involves all the stops on the data voyage for your project



Component of QA/QC

Practical tips to increase internal validity/minimize bias:

- Develop a study protocol
- Write a data management plan
- Perform data validation
- Pay attention to the details

SHEA White Paper Series

RESEARCH METHODS IN HEALTHCARE EPIDEMIOLOGY AND ANTIMICROBIAL STEWARDSHIP

RCT

- Anderson et al. ICHE 2016;37:629.

Quasi-experimental

- Schweizer et al. ICHE 2016;37:1135.

Observational studies

- Snyder et al. ICHE 2016;37:1141.

Mathematical modeling

- Barnes et al. ICHE 2016;37:1265.

Survey and qualitative research

- Safdar et al. ICHE 2016;37:1272.

Administrative and surveillance databases

- Drees et al. ICHE 2016;37:1278.

References

Whitney et al. *Epidemiol Rev* 1998;20:71-80.

Neta et al. Quality Control and Good Epidemiological Practice. In: Handbook of Epidemiology, 2nd Ed. ED: Ahrens and Pigeot.